RT Journal Article
SR Electronic
T1 The Combination of 5-FU, Leucovorin and CPT-11 (FOLFIRI) Prolongs Survival through Inhibition of Metastasis in an Orthotopic Model of Colon Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 403
OP 408
VO 30
IS 2
A1 YOKO ISHIHARA
A1 KENICHI MATSUNAGA
A1 HIROKO IIJIMA
A1 GO HASEGAWA
A1 TOSHIMITSU SUZUKI
A1 ATSUSHI SATO
A1 TOMOWO KOBAYASHI
A1 MENG YANG
A1 ROBERT M. HOFFMAN
YR 2010
UL http://ar.iiarjournals.org/content/30/2/403.abstract
AB The aim of this study was to determine the antimetastatic efficacy of the combination of 5-fluorouracil (5-FU), leucovorin (LV), and irinotecan (CPT-11) (FOLFIRI) in an orthotopic nude mouse model of GFP-HCT-116 human colon cancer-expressing green fluorescent protein (GFP). The mice were randomly divided into four groups: Group 1: saline control; Group 2: 30 mg/kg 5-FU + 90 mg/kg LV; Group 3: 5-FU + LV + 16 mg/kg CPT-11 (FOLFIRI); and Group 4: 5-FU + LV + 24 mg/kg CPT-11. 5-FU and LV were administered on days 11, 16 and 21, and CPT-11 on days 12, 18 and 22. Survival in Groups 3 and 4 was significantly longer than that in Groups 1 and 2, although no dose-dependency on CPT-11 was observed. Analysis of the primary and metastatic tumors by GFP imaging, as well as that of oncogene expression in mesentery lymph nodes, demonstrated that tumor growth and metastasis were significantly inhibited or even prevented by FOLFIRI. Pathological evaluation also demonstrated that metastasis was also inhibited by FOLFIRI. The results of the present study suggest FOLFIRI prolongs survival by inhibiting metastasis. Copyright© 2010 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved